B
Bingzhu Hua
Researcher at Nanjing University
Publications - 27
Citations - 2011
Bingzhu Hua is an academic researcher from Nanjing University. The author has contributed to research in topics: Transplantation & Mesenchymal stem cell. The author has an hindex of 17, co-authored 24 publications receiving 1704 citations. Previous affiliations of Bingzhu Hua include Nanjing Medical University.
Papers
More filters
Journal ArticleDOI
Umbilical cord mesenchymal stem cell transplantation in severe and refractory systemic lupus erythematosus
Lingyun Sun,Dandan Wang,Jun Liang,Huayong Zhang,Xuebing Feng,Hong Wang,Bingzhu Hua,Bujun Liu,Shengqin Ye,Xiang Hu,Wenrong Xu,Xiaofeng Zeng,Yayi Hou,Gary S. Gilkeson,Richard M. Silver,Liwei Lu,Songtao Shi +16 more
TL;DR: Findings indicate that UC MSCT results in amelioration of disease activity, serologic changes, and stabilization of proinflammatory cytokines in patients with severe and treatment-refractory SLE.
Journal ArticleDOI
Allogenic mesenchymal stem cells transplantation in refractory systemic lupus erythematosus: a pilot clinical study
Jun Liang,Huayong Zhang,Bingzhu Hua,Hong Wang,Liwei Lu,Songtao Shi,Yayi Hou,Xiaofeng Zeng,Gary S. Gilkeson,Lingyun Sun +9 more
TL;DR: Allogeneic MSCT in patients with refractory lupus resulted in amelioration of disease activity, improvement in serological markers and stabilisation of renal function, and MSCT appears beneficial in treatment of patients with SLE refracted to conventional treatment options.
Journal ArticleDOI
Allogeneic mesenchymal stem cell transplantation in severe and refractory systemic lupus erythematosus: 4 years of experience.
Dandan Wang,Huayong Zhang,Jun Liang,Xia Li,Xuebing Feng,Hong Wang,Bingzhu Hua,Bujun Liu,Liwei Lu,Gary S. Gilkeson,Richard M. Silver,Wanjun Chen,Songtao Shi,Lingyun Sun +13 more
TL;DR: Allogeneic MSCT resulted in the induction of clinical remission and improvement in organ dysfunction in drug-resistant SLE patients, and disease activity declined as revealed by significant changes in the SLEDAI score, levels of serum autoantibodies, albumin, and complements.
Journal ArticleDOI
Allogeneic mesenchymal stem cell transplantation in seven patients with refractory inflammatory bowel disease
Jun Liang,Huayong Zhang,Dandan Wang,Xuebing Feng,Hong Wang,Bingzhu Hua,Bujun Liu,Lingyun Sun +7 more
TL;DR: The authors report the experience of allogeneic MSCT in seven patients with IBD and suggest that administration of autologous bone marrow-derived mesenchymal stem cells is safe and feasible in the treatment of refractory Crohn's disease.
Journal ArticleDOI
Allogeneic mesenchymal stem cells transplantation in treatment of multiple sclerosis
TL;DR: It is postulate that mesenchymal stem cells have a potent immunosuppressive effect in vivo and are transplanted in a patient with refractory progressive MS and the disease course was stabilized after the transplantation.